{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:29:51Z","timestamp":1790281791522,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council UK","doi-asserted-by":"crossref","award":["G0800629"],"award-info":[{"award-number":["G0800629"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary Sj\u00f6gren\u2019s syndrome (pSS) is an autoimmune disease characterised by an increased risk for non-Hodgkin lymphoma (NHL) development. Ectopic germinal centre (GC) in the salivary gland is associated with increased NHL risk in pSS, and the chemokine CXCL13 is implicated in B-cell migration and GC formation. Serum CXCL13 concentrations were quantified by ELISA in 48 healthy individuals, 273 pSS patients without NHL (pSS-nonL), and 38 pSS patients with NHL (pSS-NHL+) from the United Kingdom Primary Sj\u00f6gren\u2019s Syndrome Registry cohort. PSS-nonL patients were stratified into low risk (LR), moderate risk (MR) and high risk (HR) groups according to the lymphoma risk score proposed by Fragkioudaki et al. Differences in serum CXCL13 levels among groups were analysed using the Wilcoxon method. Also, changes in serum CXCL13 over a time period of at least 1\u00a0year and a median 4 years were assessed for 200 pSS-nonL\u00a0and 8 pSS-NHL+ patients. In addition, associations of serum CXCL13 with B-cell and inflammatory markers were investigated by correlation analyses and logistic regression. Serum CXCL13 levels were higher in all pSS groups compared to controls (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and in pSS-NHL+ compared to pSS-nonL patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.0204). LR patients had lower CXCL13 levels than MR patients (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and pSS-NHL+ patients (<jats:italic>p<\/jats:italic>\u2009=\u20090.0008). CXCL13 levels remained stable over the study period for all pSS groups. CXCL13 was associated (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0005) with Immunoglobulin G (IgG), B-cell activating factor, \u03b22 microglobulin, combined free light chains, \u03ba and \u03bb light chains, anti-Ro\/SSA, anti-La\/SSB, and erythrocyte sedimentation rate. IgG and C3 controlled for age and gender were significantly associated with NHL risk in pSS. Serum CXCL13 levels were elevated in pSS-NHL+ and MR patients compared to LR patients and remained stable over time. Further study is required to investigate the role of CXCL13 in pSS-associated NHL risk.<\/jats:p>","DOI":"10.1007\/s00296-020-04524-5","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T12:02:52Z","timestamp":1581422572000},"page":"541-548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1007","volume":"40","author":[{"name":"UK primary Sj\u00f6gren\u2019s syndrome registry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4361-7022","authenticated-orcid":false,"given":"Emmanuella Young","family":"Traianos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6268-5509","authenticated-orcid":false,"given":"Dennis","family":"Lendrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-9948","authenticated-orcid":false,"given":"Simon","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Hargreaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Macrae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Rachael","family":"Tarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5539-388X","authenticated-orcid":false,"given":"Wan-Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"issue":"5","key":"4524_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0049-0172(96)80019-9","volume":"25","author":"J Anaya","year":"1996","unstructured":"Anaya J, Mcguff H, Banks P, Talal N (1996) Clinicopathological factors relating malignant lymphomawith Sj\u00f6gren\u2019s syndrome. Semin Arthritis Rheum 25(5):337\u2013346. https:\/\/doi.org\/10.1016\/S0049-0172(96)80019-9","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"4524_CR2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/ard.2005.041186","volume":"65","author":"E Theander","year":"2006","unstructured":"Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT (2006) Lymphoma and other malignancies in primary Sjogren\u2019s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65(6):796\u2013803. https:\/\/doi.org\/10.1136\/ard.2005.041186","journal-title":"Ann Rheum Dis"},{"key":"4524_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.semarthrit.2011.04.006","volume":"41","author":"R Solans-Laque","year":"2011","unstructured":"Solans-Laque R, Lopez-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell Tarres M (2011) Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren\u2019s syndrome. Semin Arthritis Rheum 41:415\u2013423. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.04.006","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"4524_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/jnci\/djj004","volume":"98","author":"K Smedby","year":"2006","unstructured":"Smedby K, Hjalgrim H, Askling J, Chang E, Gregersen H, Porwit-MacDonald A et al (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. JNCI J Natl Cancer Inst 98(1):51\u201360. https:\/\/doi.org\/10.1093\/jnci\/djj004","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"6","key":"4524_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.berh.2007.09.001","volume":"21","author":"A Tzioufas","year":"2007","unstructured":"Tzioufas A, Voulgarelis M (2007) Update on Sj\u00f6gren\u2019s syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 21(6):989\u20131010. https:\/\/doi.org\/10.1016\/j.berh.2007.09.001","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"8","key":"4524_CR6","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/ard.2010.144782","volume":"70","author":"E Theander","year":"2011","unstructured":"Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R et al (2011) Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren\u2019s syndrome. Ann Rheum Dis 70(8):1363\u20131368. https:\/\/doi.org\/10.1136\/ard.2010.144782","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4524_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.pharmthera.2006.06.002","volume":"112","author":"A Sutherland","year":"2006","unstructured":"Sutherland A, Mackay F, Mackay C (2006) Targeting BAFF: Immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 112(3):774\u2013786. https:\/\/doi.org\/10.1016\/j.pharmthera.2006.06.002","journal-title":"Pharmacol Ther"},{"key":"4524_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaut.2013.04.005","volume":"51","author":"A Nezos","year":"2014","unstructured":"Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas A et al (2014) B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren\u2019s syndrome. J Autoimmun 51:89\u201398. https:\/\/doi.org\/10.1016\/j.jaut.2013.04.005","journal-title":"J Autoimmun"},{"issue":"2","key":"4524_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","volume":"52","author":"L Quartuccio","year":"2012","unstructured":"Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M et al (2012) BLyS upregulation in Sjogren\u2019s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology 52(2):276\u2013281. https:\/\/doi.org\/10.1093\/rheumatology\/kes180","journal-title":"Rheumatology"},{"key":"4524_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.smim.2003.08.002","volume":"15","author":"T Cupedo","year":"2003","unstructured":"Cupedo T, Mebius RE (2003) Role of chemokines in the development of secondary and tertiary lymphoid tissues. Semin Immunol 15:243\u2013248. https:\/\/doi.org\/10.1016\/j.smim.2003.08.002","journal-title":"Semin Immunol"},{"issue":"7","key":"4524_CR11","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.4049\/jimmunol.180.7.5130","volume":"180","author":"F Barone","year":"2008","unstructured":"Barone F, Bombardieri M, Rosado M, Morgan P, Challacombe S, De Vita S et al (2008) CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjogren\u2019s syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization. J Immunol 180(7):5130\u20135140. https:\/\/doi.org\/10.4049\/jimmunol.180.7.5130","journal-title":"J Immunol"},{"issue":"1","key":"4524_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2007.12.001","volume":"20","author":"CD Allen","year":"2008","unstructured":"Allen CD, Cyster JG (2008) Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol 20(1):14\u201325. https:\/\/doi.org\/10.1016\/j.smim.2007.12.001","journal-title":"Semin Immunol"},{"issue":"7","key":"4524_CR13","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1002\/eji.200636136","volume":"36","author":"A-U Rasheed","year":"2006","unstructured":"Rasheed A-U, Rahn H-P, Sallusto F, Lipp M, M\u00fcller G (2006) Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression. Eur J Immunol 36(7):1892\u20131903. https:\/\/doi.org\/10.1002\/eji.200636136","journal-title":"Eur J Immunol"},{"issue":"6","key":"4524_CR14","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0092-8674(00)81798-5","volume":"87","author":"R F\u00f6rster","year":"1996","unstructured":"F\u00f6rster R, Mattis A, Kremmer E, Wolf E, Brem G, Lipp M (1996) A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87(6):1037\u20131047. https:\/\/doi.org\/10.1016\/S0092-8674(00)81798-5","journal-title":"Cell"},{"key":"4524_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/35018581","volume":"406","author":"KM Ansel","year":"2000","unstructured":"Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD, Browning JL, Lipp M, Cyster JG (2000) A chemokine-driven feedback loop organizes lymphoid follicles. Nature 406:309\u2013314. https:\/\/doi.org\/10.1038\/35018581","journal-title":"Nature"},{"issue":"5","key":"4524_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S1074-7613(00)80199-5","volume":"12","author":"S Luther","year":"2000","unstructured":"Luther S, Lopez T, Bai W, Hanahan D, Cyster J (2000) BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12(5):471\u2013481. https:\/\/doi.org\/10.1016\/S1074-7613(00)80199-5","journal-title":"Immunity"},{"issue":"6","key":"4524_CR17","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1182\/blood-2011-01-332106","volume":"118","author":"J Saez de Guinoa","year":"2011","unstructured":"Saez de Guinoa J, Barrio L, Mellado M, Carrasco Y (2011) CXCL13\/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. Blood 118(6):1560\u20131569. https:\/\/doi.org\/10.1182\/blood-2011-01-332106","journal-title":"Blood"},{"issue":"6","key":"4524_CR18","doi-asserted-by":"publisher","first-page":"R182","DOI":"10.1186\/ar3507","volume":"13","author":"R Fava","year":"2011","unstructured":"Fava R, Kennedy S, Wood S, Bolstad A, Bienkowska J, Papandile A et al (2011) Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sj\u00f6gren\u2019s syndrome. Arthritis Res Ther 13(6):R182. https:\/\/doi.org\/10.1186\/ar3507","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"4524_CR19","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.39315","volume":"67","author":"G Nocturne","year":"2015","unstructured":"Nocturne G, Seror R, Fogel O, Belkhir R, Boudaoud S, Saraux A et al (2015) CXCL13 and CCL11 serum levels and lymphoma and disease activity in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol 67(12):3226\u20133233. https:\/\/doi.org\/10.1002\/art.39315","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4524_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/rheumatology\/kez255","volume":"59","author":"S Colafrancesco","year":"2019","unstructured":"Colafrancesco S, Priori R, Smith C, Minniti A, Iannizzotto V, Pipi E et al (2019) CXCL13 as biomarker for histological involvement in Sj\u00f6gren\u2019s syndrome. Rheumatology 59(1):165\u2013170. https:\/\/doi.org\/10.1093\/rheumatology\/kez255","journal-title":"Rheumatology"},{"issue":"48","key":"4524_CR21","doi-asserted-by":"publisher","first-page":"e8675","DOI":"10.1097\/MD.0000000000008675","volume":"96","author":"C Fang","year":"2017","unstructured":"Fang C, Luo T, Lin L (2017) The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus. Medicine 96(48):e8675. https:\/\/doi.org\/10.1097\/MD.0000000000008675","journal-title":"Medicine"},{"issue":"1","key":"4524_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/rheumatology\/keq240","volume":"50","author":"W Ng","year":"2010","unstructured":"Ng W, Bowman S, Griffiths B (2010) United Kingdom primary Sjogren\u2019s syndrome registry\u2014a united effort to tackle an orphan rheumatic disease. Rheumatology 50(1):32\u201339. https:\/\/doi.org\/10.1093\/rheumatology\/keq240","journal-title":"Rheumatology"},{"issue":"25","key":"4524_CR23","doi-asserted-by":"publisher","first-page":"e3766","DOI":"10.1097\/MD.0000000000003766","volume":"95","author":"S Fragkioudaki","year":"2016","unstructured":"Fragkioudaki S, Mavragani C, Moutsopoulos H (2016) Predicting the risk for lymphoma development in Sjogren syndrome. Medicine 95(25):e3766. https:\/\/doi.org\/10.1097\/MD.0000000000003766","journal-title":"Medicine"},{"issue":"7","key":"4524_CR24","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/rheumatology\/key063","volume":"57","author":"K James","year":"2018","unstructured":"James K, Chipeta C, Parker A, Harding S, Cockell S, Gillespie C et al (2018) B-cell activity markers are associated with different disease activity domains in primary Sj\u00f6gren\u2019s syndrome. Rheumatology 57(7):1222\u20131227. https:\/\/doi.org\/10.1093\/rheumatology\/key063","journal-title":"Rheumatology"},{"issue":"5","key":"4524_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","volume":"29","author":"F Skopouli","year":"2000","unstructured":"Skopouli F, Dafni U, Ioannidis J, Moutsopoulos H (2000) Clinical evolution, and morbidity and mortalityof primary Sj\u00f6gren\u2019s syndrome. Semin Arthritis Rheum 29(5):296\u2013304. https:\/\/doi.org\/10.1016\/S0049-0172(00)80016-5","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"4524_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/art.10221","volume":"46","author":"J Ioannidis","year":"2002","unstructured":"Ioannidis J, Vassiliou V, Moutsopoulos H (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 46(3):741\u2013747. https:\/\/doi.org\/10.1002\/art.10221","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4524_CR27","doi-asserted-by":"publisher","first-page":"e0116189","DOI":"10.1371\/journal.pone.0116189","volume":"10","author":"A Papageorgiou","year":"2015","unstructured":"Papageorgiou A, Ziogas D, Mavragani C, Zintzaras E, Tzioufas A, Moutsopoulos H et al (2015) Predicting the outcome of Sjogren\u2019s syndrome-associated non-Hodgkin\u2019s lymphoma patients. PLoS ONE 10(2):e0116189. https:\/\/doi.org\/10.1371\/journal.pone.0116189","journal-title":"PLoS ONE"},{"issue":"6","key":"4524_CR28","doi-asserted-by":"publisher","first-page":"888","DOI":"10.7326\/0003-4819-89-6-888","volume":"89","author":"S Kassan","year":"1978","unstructured":"Kassan S, Thomas T, Moutsopoulos H, Hoover R, Kimberly R, Budman D et al (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6):888. https:\/\/doi.org\/10.7326\/0003-4819-89-6-888","journal-title":"Ann Intern Med"},{"issue":"1","key":"4524_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0116189","volume":"91","author":"M Voulgarelis","year":"2012","unstructured":"Voulgarelis M, Ziakas P, Papageorgiou A, Baimpa E, Tzioufas A, Moutsopoulos H (2012) Prognosis and outcome of non-Hodgkin lymphoma in primary Sj\u00f6gren syndrome. Medicine 91(1):1\u20139. https:\/\/doi.org\/10.1371\/journal.pone.0116189","journal-title":"Medicine"},{"issue":"1\u20132","key":"4524_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jaut.2012.01.002","volume":"39","author":"A Tzioufas","year":"2012","unstructured":"Tzioufas A, Kapsogeorgou E, Moutsopoulos H (2012) Pathogenesis of Sj\u00f6gren\u2019s syndrome: what we know and what we should learn. J Autoimmun 39(1\u20132):4\u20138. https:\/\/doi.org\/10.1016\/j.jaut.2012.01.002","journal-title":"J Autoimmun"},{"key":"4524_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jaut.2013.10.002","volume":"51","author":"L Quartuccio","year":"2014","unstructured":"Quartuccio L, Isola M, Baldini C, Priori R, Bartoloni Bocci E, Carubbi F et al (2014) Biomarkers of lymphoma in Sj\u00f6gren\u2019s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 51:75\u201380. https:\/\/doi.org\/10.1016\/j.jaut.2013.10.002","journal-title":"J Autoimmun"},{"issue":"7","key":"4524_CR32","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.4049\/jimmunol.179.7.4929","volume":"179","author":"M Bombardieri","year":"2007","unstructured":"Bombardieri M, Barone F, Humby F, Kelly S, McGurk M, Morgan P et al (2007) Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis. J Autoimmun 179(7):4929\u20134938. https:\/\/doi.org\/10.4049\/jimmunol.179.7.4929","journal-title":"J Autoimmun"},{"issue":"4","key":"4524_CR33","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/1529-0131(200004)43:4%3c908::AID-ANR24%3e3.0.CO;2-K","volume":"43","author":"T Martin","year":"2001","unstructured":"Martin T, Weber JC, Levallois H, Labouret N, Soley A, Koenig S et al (2001) Salivary gland lymphomas in patients with Sjogren\u2019s syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 43(4):908\u2013916. https:\/\/doi.org\/10.1002\/1529-0131(200004)43:4%3c908:AID-ANR24%3e3.0.CO;2-K","journal-title":"Arthritis Rheum"},{"issue":"10","key":"4524_CR34","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1073\/pnas.1520112113","volume":"113","author":"C Havenar-Daughton","year":"2016","unstructured":"Havenar-Daughton C, Lindqvist M, Heit A, Wu J, Reiss S, Kendric K et al (2016) CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci 113(10):2702\u20132707. https:\/\/doi.org\/10.1073\/pnas.1520112113","journal-title":"Proc Natl Acad Sci"},{"key":"4524_CR35","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/annrheumdis-2019-eular.4134","volume":"78","author":"E Traianos","year":"2019","unstructured":"Traianos E, Locke J, Lendrem D et al (2019) FRI0652 serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 78:1023\u20131024. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.4134","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04524-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-020-04524-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-020-04524-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T06:28:25Z","timestamp":1612938505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-020-04524-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4524"],"URL":"https:\/\/doi.org\/10.1007\/s00296-020-04524-5","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"assertion":[{"value":"4 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author Professor Simon Bowman has provided consultancy services in the area of Sj\u00f6gren\u2019s syndrome for the following companies: Celgene, Eli Lilly, Glenmark, GSK, Medimmune, Novartis, Ono, Pfizer, Takeda, UCB. Author Emmanuella Young Traianos declares that she has no conflict of interest. Author Dr. James Locke declares that he has no conflict of interest. Author Dr. Dennis Lendrem declares that he has no conflict of interest. Author Ben Hargreaves declares that he has no conflict of interest. Author Victoria Macrae declares that she has no conflict of interest. Author Dr. Jessica Rachael Tarn declares that she has no conflict of interest. Author Professor Wan-Fai Ng declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Research ethics approval was granted by the UK North-West Research Ethics Committee. All procedures involving human participants in this study were performed in accordance with the Newcastle University\u2019s guidelines on the use of humans in research which are based on those established by the HRA\u2019s Research Ethics Service, the 1964 Declaration of Helsinki and its later amendments, and the Human Rights Act (1998).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}